Zhenmai Biology, when the industry is in progress
will take you to understand gene industry news for a week On June 2, the journal Nature published back-to-back three studies from the Owen J. Sansom team from the Beeson Cancer Research Institute in the UK, in conjunction with the University of Helsinki, Finland, and Pekka Katajisto's team, Cambridge University Benjamin D. Simons team, together with the work of Bon-Kyoung Koo's team from Cambridge University, UK and Louis Vermeulen's team at Amsterdam University Medical Center, the Netherlands, explored how intestinal stem cells can restore the competitiveness of wild-type cells by inhibiting Apc mutation , thereby improving the health of normal cells, limiting the proliferation and expansion of precancerous clones, and providing preventive strategies for high-risk groups of colorectal cancer.
Northwestern University Yue Feng's group proposes a new method to identify enhancer hijacking
html On June 3, Northwestern University Yue Feng's group published a paper in the journal Nature Methods, proposing that chromatin spatial interaction data based on the whole genome ( Hi-C) A new approach to identify enhancer hijacking on cancer genomes. This method takes chromatin interaction data and SV as input, and by assembling the local genome of tumor cells, removes the data bias caused by copy number variation, SV heterozygosity and heterogeneity, and then identifies SV-mediated the "new chromatin ring".Zhu Weiguo's team reveals a new mechanism by which histone participates in DNA replication
On June 2, Shenzhen University Professor Zhu Weiguo's team published a long article online on PNAS, revealing that histone methylation is involved in regulating the activation of ATR signaling pathway , and promotes an important function of restarting stalled DNA replication forks.
Nature sub-issue: Discovery of gene mutation that causes ALS, siRNA is expected to be a treatment Clinical reports are published in the medical journal Nature Medicine. This clinical study not only describes a group of rare single-gene mutations behind an aggressive form of early-onset ALS, but also suggests that direct metabolic disturbance is a causative factor in disease progression. In addition, the research team conducted experiments using siRNA to try to inhibit the newly discovered mutant SPLTC1 gene. The team's experiments on skin cells from patients showed that siRNA both reduced the level of SPLTC1 gene expression and restored sphingomyelin to normal levels.
Tsinghua University Wang Xiaowo's team published the integrated analysis process of cell-free DNA sequencing data software package
On May 27, Professor Wang Xiaowo's team from the Department of Automation of Tsinghua University cooperated with Tsinghua-Fuzhou Institute of Data Technology and published it on Bioinformatics In the research article, a systematic data analysis software package "cfDNApipe" for cfDNA whole-genome sequencing (WGS) and whole-genome methylation sequencing (WGBS) was developed.
Professor Shi Yi's team developed nanobody spray to prevent and treat new coronavirus infection, animal experiments show the protective effect , demonstrated a nanobody-based spray therapy against the new coronavirus (SARS-CoV-2). In experiments with hamsters, the spray prevented severe symptoms caused by the new coronavirus infection.
Policy Specification
The State Food and Drug Administration comprehensively issued an announcement on the implementation of the " Regulations on the Supervision and Administration of Medical Devices"
On May 31, the State Food and Drug Administration issued a comprehensive announcement on the implementation of the "Regulations on the Supervision and Administration of Medical Devices". Announcement on the implementation of the new "Regulations" related matters including:
I. About the full implementation of the medical device registrant and filer system About medical device production license and record management
V.Regarding medical device business license and record management
VI.On the investigation and punishment of medical device violations
Capital & Industry Dynamic
Sincere DiagnosticsCompleted nearly 600 million yuan in Series B financing
June 4 On March 1, Simcere Diagnostics announced the completion of its Series B financing of nearly RMB 600 million. This round of financing was led by CITIC Securities Investment and CITIC Medical Fund, followed by Yingke Capital, Houxin Jiantou, Jinpu Guotiao, Chuangrui Investment, Renpu Medical Fund, Hongcheng Investment, Jinyu Bogor and Nanjing Innovation Investment. Tianhui Capital continued to support. Taihe Capital acted as the exclusive financial advisor for this financing.
Diying Bio received nearly 100 million yuan in Series A investment, focusing on a new generation of DNA synthesis technology
On June 5, Diying Bio announced that it had received nearly 100 million yuan in Series A investment. This round is led by Heyu Capital, and the old shareholders Volcanic Stone Capital and Chaosheng Capital will continue to follow up. The funds will be used to further consolidate the company's new generation of ultra-high-throughput DNA synthesis technology, and the currently commercialized DYHOW new generation DNA The synthesis throughput of the synthesis platform has been increased to one million levels, while the company's product pipeline layout has been improved, and new R&D and production bases have been expanded.
Golden Key Medical has again received investment from Taikang and Yuanhe Yuandian to jointly promote the establishment of the industry standard for infection genetic testing
According to a report from Arterial Network on June 1, Golden Key Medical announced that it has added two more strategic investors in the C+ round of financing, namely Taikang Investment and Yuanhe Origin, Jinkey Medical just announced that it has received hundreds of millions of strategic investment from CPE Yuanfeng. It is understood that after this round of financing, Golden Key Medical will make better use of the high-quality resources and professional investment layout of CPE Yuanfeng, Taikang Group and Yuanhe Yuandian in the medical field to accelerate the development and promotion of infectious disease genetic testing products.
Smibio completed a new round of financing of nearly 200 million US dollars to accelerate the new crown vaccine clinical research
On June 1st, Siwei announced that it has officially completed a new round of financing of nearly 200 million US dollars. This round of financing was funded by China Merchants Health, Hong Fir Capital China Fund, Jinglin Investment, WuXi AppTec co-led the investment, Aobo Capital, Shangxun Investment, Guoxin Guotong, CMB International, Kelly Yifang Capital, Everbright Capital, Qingpine Capital, CITIC Securities Investment and other majors Medical and health investment institutions followed suit. The financing is mainly used to accelerate the clinical research of the new crown vaccine, the construction of the GMP production workshop, and the expansion of the research and development pipeline.
Deyun Kangrui acquired Microorganisms, and strived to create an overall solution for single-cell capture, sequencing, and bioinformatics analysis
On May 25, Deyun Kangrui officially announced the completion of the acquisition, integration and equity change of Microorganisms. After the completion of the merger and acquisition, Deyun Kangrui will incorporate the single-cell enrichment and detection platform of Microbial, two single-cell sequencing platforms with different principles, and single-cell bioinformatics analysis platform based on the existing single-cell enrichment and detection platform. Cell Sequencing Platform and Microsphere Encoding Technology.
Disclaimer: This industry dynamic information comes from BioArt, Xiaoke Life, E-Pharma World, Sequencing China, Academic Jingwei, China Device Review, Arterial Network, Yimaike, etc. We very much respect the copyright of the original author, if any copyright issues are involved , please contact the editor of this headline number to delete it in time, thank you!
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-